Status:

COMPLETED

Diclofenac Sodium Topical Gel to Reduce Injection Site Discomfort in Patients Taking Glatiramer Acetate

Lead Sponsor:

Brown, Theodore R., M.D., MPH

Collaborating Sponsors:

Teva Neuroscience, Inc.

Conditions:

Multiple Sclerosis

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

The purpose of this study is to assess the effect of Diclofenac Sodium Topical Gel (DSTG) on injection site reaction following self-administer glatiramer acetate in people with Multiple Sclerosis.

Detailed Description

A 4 week study with active or placebo medication at randomization and switch treatment at 2-week crossover visit (2 weeks on each arm). There will be a total of 3 visits to the clinic. Subjects will r...

Eligibility Criteria

Inclusion

  • Diagnosis of Multiple Sclerosis (MS) made at least 3 months prior based on McDonald or Poser criteria.
  • Age 18 or more
  • Ongoing treatment with glatiramer acetate (Copaxone) for three months or more.
  • No MS exacerbation for 60 days prior to screening.
  • Mean score of greater than or equal to 1.0 on screening Local Injection Site Reaction scale of last 3 days.
  • Written informed consent.

Exclusion

  • Regular use of any non-steroidal anti-inflammatory drug (NDAID), except Asprin (\<325 mg daily), between screening and end of study.
  • Any contraindication to Diclofenac Sodium Topical Gel (DSTG)
  • allergy to DSTG or any NSAID.
  • history of asthma, urticaria, or other allergic reaction after taking any NSAID.
  • Females who are breast feeding, pregnant or have potential to become pregnant during the course of the study(fertile and unwilling/unable to use effective contraceptive measures).
  • Cognitive deficits that would interfere with the subject's ability to give informed consent or preform study testing.
  • Any other serious and/or unstable medical condition.

Key Trial Info

Start Date :

January 1 2011

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 1 2013

Estimated Enrollment :

40 Patients enrolled

Trial Details

Trial ID

NCT01454791

Start Date

January 1 2011

End Date

March 1 2013

Last Update

March 5 2015

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

MS Center at Evergreen Healthcare

Kirkland, Washington, United States, 98034